We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Rotating Frame Relaxation and Diffusion Weighted Imaging of Human Gliomas (RODIG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02186262
Recruitment Status : Completed
First Posted : July 10, 2014
Last Update Posted : June 14, 2018
Sponsor:
Information provided by (Responsible Party):
Heikki Minn, Turku University Hospital

Brief Summary:

Grading of gliomas is of significant clinical importance since the prognosis as well as the treatment of choice are distinct in low-grade and high-grade gliomas. With standard MRI modalities, however, a reliable distinction is often impossible. Moreover, the gold standard for glioma grading by histopathology may also have limitations due to unrepresentative tumor samples. Therefore, more advanced MRI techniques are urgently needed that would have higher sensitivity and specificity in the definition of tumor type, grade and extent.

Assessment of radiologic response for high-grade gliomas utilizes the updated RANO criteria 12 weeks after completion of chemoradiotherapy. However, there is an urgent need to identify nonresponding patients earlier, preferentially midtreatment in order to consider alternative treatment strategies. Imaging biomarkers, such as diffusion weighted MR imaging (DWI), have provided promising results in assessing early treatment response. Furthermore, a serum biomarker with diagnostic value could improve tumor follow-up and clinical management of gliomas.

The aim of our study is to develop novel imaging protocols suitable for the magnetic resonance imaging (MRI) of glioma using advanced MRI techniques such as rotating frame imaging, novel DWI acquisition and post-processing methods We also study the correlation between advanced MRI parameters and histopathology of the tumor specimen. In addition, early treatment response is assessed with advanced MRI parameters at 3 week and 10 week after initiation of radiotherapy. Finally, our objective is to study the association between serum biomarkers and corresponding MRI with potential tumor progression.


Condition or disease
Low Grade Glioma Malignant Glioma

Layout table for study information
Study Type : Observational
Actual Enrollment : 36 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Rotating Frame Relaxation and Diffusion Weighted Imaging of Human Gliomas
Study Start Date : March 2014
Actual Primary Completion Date : December 2017
Actual Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Body Weight

Group/Cohort
Primary gliomas, Recurrent gliomas



Primary Outcome Measures :
  1. Rotating frame relaxation and diffusion weighted MR parameters in the tumor and surrounding area [ Time Frame: Prior to surgical resection ]
    Different MR relaxation parameters (T1rho-adiabatic,T1rho-cw T2rho-adiabatic,... ) and diffusion values (ADCm, ADCk, K, f, Df, Ds,...) will be measured in the tumor and surrounding area. The quantitative values will be correlated with cancer aggressiveness and tissue bio-markers. Furthermore, tumor volume will be estimated using different quantitative values.


Secondary Outcome Measures :
  1. Changes in rotating frame relaxation and diffusion weighted MR parameters in the residual tumor during therapy [ Time Frame: Before, after 3 weeks, and after 10 weeks of the beginning of radiotherapy, and 12 weeks after completion of radiotherapy ]
    Change in the different MR relaxation parameters (T1rho-adaibatic,T1rho-cw T2rho-adiabatic,... ) and diffusion values (ADCm, ADCk, K, f, Df, Ds,...) during tumor therapy will be estimated from repeated MR examinations performed before, after 3 weeks, and after 10 weeks of the beginning of radiotherapy, and 12 weeks after completion of radiotherapy.


Biospecimen Retention:   Samples With DNA
Whole blood, frozen tumor tissue


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with a brain tumor scheduled for a surgical resection at the Turku University Hospital, Finland.
Criteria

Inclusion Criteria:

  • Age: 18 to 80 years old
  • Language spoken: Finnish or Swedish
  • Performance status: Karnofsky score 70 or better or WHO performance status 2 or better
  • Supratentorial primary malignant glioma (the diagnosis is based on radiological and clinical grounds)
  • Supratentorial recurrent glioma based on MRI and/or [11C]methionine PET imaging
  • Patient is scheduled to either surgery or stereotactic biopsy
  • Mental status: Patients must be able to understand the meaning of the study
  • Informed consent: The patient must sign the appropriate Ethical Committee (EC) approved informed consent documents in the presence of the designated staff

Exclusion Criteria:

  • Prior medical history: Patient must have no history of serious cardiovascular, liver or kidney disease
  • Any psychiatric condition that compromises the subject's ability to participate in the study
  • Infections: Patient must not have an uncontrolled serious infection
  • No contraindications for MRI (cardiac pacemaker, intracranial clips etc)
  • Patient must not have claustrophobia with serious symptoms
  • Pregnant or lactating women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02186262


Locations
Layout table for location information
Finland
Turku University Hospital
Turku, Finland, FI-20520
Sponsors and Collaborators
Turku University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Heikki R Minn, Professor Turku University Hospital, Department of Oncology and Radiotherapy
Layout table for additonal information
Responsible Party: Heikki Minn, Professor, Turku University Hospital
ClinicalTrials.gov Identifier: NCT02186262    
Other Study ID Numbers: 1234
First Posted: July 10, 2014    Key Record Dates
Last Update Posted: June 14, 2018
Last Verified: June 2018
Keywords provided by Heikki Minn, Turku University Hospital:
Glioma
MRI
Rotating frame relaxation
DWI
treatment response
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue